UA100497C2 - Комбинированное лечение сахарного диабета - Google Patents
Комбинированное лечение сахарного диабетаInfo
- Publication number
- UA100497C2 UA100497C2 UAA200902891A UAA200902891A UA100497C2 UA 100497 C2 UA100497 C2 UA 100497C2 UA A200902891 A UAA200902891 A UA A200902891A UA A200902891 A UAA200902891 A UA A200902891A UA 100497 C2 UA100497 C2 UA 100497C2
- Authority
- UA
- Ukraine
- Prior art keywords
- diabetes mellitus
- combination treatment
- treatment
- type
- hexahydrophenanthridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к комбинированному применению (2R,4aR,10bR)-6-(2,6-диметоксипиридин-3-ил)-9-этокси-8-метокси-1,2,3,4,4а,10b-гексагидрофенантридин-2-ола или его фармацевтически приемлемой соли и римонабанта или его фармацевтически приемлемой соли для лечения сахарного диабета типа 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06120305 | 2006-09-07 | ||
PCT/EP2007/059253 WO2008028914A1 (en) | 2006-09-07 | 2007-09-04 | Combination treatment for diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
UA100497C2 true UA100497C2 (ru) | 2013-01-10 |
Family
ID=38441474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200902891A UA100497C2 (ru) | 2006-09-07 | 2007-09-04 | Комбинированное лечение сахарного диабета |
Country Status (17)
Country | Link |
---|---|
US (2) | US20100179131A1 (ru) |
EP (2) | EP2063890A1 (ru) |
JP (1) | JP2010502670A (ru) |
KR (1) | KR20090047546A (ru) |
CN (1) | CN101511364B (ru) |
AU (1) | AU2007293885A1 (ru) |
BR (1) | BRPI0716134A2 (ru) |
CA (1) | CA2662084A1 (ru) |
EA (1) | EA200900392A1 (ru) |
IL (1) | IL196869A0 (ru) |
ME (1) | MEP8509A (ru) |
MX (1) | MX2009002282A (ru) |
NO (1) | NO20091260L (ru) |
NZ (1) | NZ574710A (ru) |
UA (1) | UA100497C2 (ru) |
WO (1) | WO2008028914A1 (ru) |
ZA (1) | ZA200900501B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS56632B1 (sr) | 2008-10-17 | 2018-03-30 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
AU2009238272B2 (en) * | 2009-11-13 | 2014-05-08 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む2型糖尿病の治療方法 |
CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
AU2009238271B8 (en) * | 2009-11-13 | 2014-05-15 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
CN101747426B (zh) * | 2009-12-18 | 2013-01-16 | 深圳翰宇药业股份有限公司 | 一种合成普兰林肽的方法 |
CN101798301A (zh) * | 2010-04-13 | 2010-08-11 | 漆又毛 | 吡咯烷基嘧啶甲磺酰胺衍生物及制备方法 |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
TWI462739B (zh) * | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
TR201107482A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
TR201101809A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
EP2468268B1 (en) * | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
US10132302B2 (en) * | 2013-07-22 | 2018-11-20 | Baxter International Inc. | Infusion pump including reverse loading protection |
EP3139948B1 (en) * | 2014-05-07 | 2020-03-04 | Novo Nordisk A/S | Treatment of diabetes type 1 using glp-1 and anti-il-21 |
CA2950695C (en) | 2014-06-08 | 2022-12-06 | REMD Biotherapeutics, Inc | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
MX2017007699A (es) | 2014-12-12 | 2017-09-18 | Sanofi Aventis Deutschland | Formulacion de proporcion fija de insulina glargina/lixisenatida. |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
CA3034956A1 (en) * | 2016-08-26 | 2018-03-01 | Takeda Gmbh | Treatment of nonalcoholic fatty liver disease |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
DE3856378T2 (de) | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
DK0567626T3 (da) | 1991-11-19 | 2001-12-17 | Amylin Pharmaceuticals Inc | Amylin-agonist-peptider og anvendelse deraf |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
DE4439947A1 (de) | 1994-11-09 | 1996-05-15 | Boehringer Mannheim Gmbh | 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
IL118474A (en) | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
WO1996039385A1 (en) | 1995-06-06 | 1996-12-12 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
PL192359B1 (pl) | 1996-08-30 | 2006-10-31 | Novo Nordisk As | Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37) |
EP0981611A1 (en) | 1997-02-05 | 2000-03-01 | 1149336 Ontario Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
WO1999014239A1 (de) | 1997-09-12 | 1999-03-25 | Wolf Georg Forssmann | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
WO2000001495A1 (en) | 1998-07-02 | 2000-01-13 | Millipore Corporation | Process for coating a solid surface with a liquid composition |
FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
DE19844547C2 (de) | 1998-09-29 | 2002-11-07 | Aventis Pharma Gmbh | Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
WO2000034331A2 (en) | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
HU225917B1 (en) | 1999-09-16 | 2007-12-28 | Tanabe Seiyaku Co | Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use |
TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
WO2001035979A2 (en) * | 1999-11-13 | 2001-05-25 | Icos Corporation | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
CN1740182A (zh) | 1999-12-22 | 2006-03-01 | 症变治疗公司 | 新的双氨基化膦酸酯前药 |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
CA2419033A1 (en) | 2000-08-11 | 2002-02-21 | Earl Michael Gibbs | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
US20020165237A1 (en) * | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
MXPA03006936A (es) | 2001-02-02 | 2003-11-18 | Pfizer | Tratamiento de diabetes mellitus. |
PL368051A1 (en) | 2001-06-07 | 2005-03-21 | Eli Lilly And Company | Modulators of peroxisome proliferator activated receptors |
KR20040015298A (ko) | 2001-06-27 | 2004-02-18 | 스미스클라인 비참 코포레이션 | 디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘 |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
DE10150517A1 (de) | 2001-10-12 | 2003-04-17 | Merck Patent Gmbh | Verwendung von Phosphodiesterase IV-Inhibitoren |
MXPA04004170A (es) | 2001-11-02 | 2004-09-06 | Pfizer Prod Inc | Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9. |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
BR0308415A (pt) | 2002-03-14 | 2005-02-15 | Bayer Pharmaceuticals Corp | Métodos de tratamento de diabetes usando-se inibidores de pde11a |
MXPA05009242A (es) | 2003-03-17 | 2006-04-18 | Pfizer Prod Inc | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
CA2530316A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines as pde10 inhibitors |
EP1649282A4 (en) * | 2003-07-07 | 2007-08-29 | Webb Waring Inst | PROCESS FOR PREDICTING THE DEVELOPMENT OF AUTOIMMUNE DISEASES AND TREATMENT THEREOF |
EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
JP2007504201A (ja) * | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 真性糖尿病の治療のためのpde4阻害剤の使用 |
WO2005085225A1 (en) * | 2004-03-03 | 2005-09-15 | Altana Pharma Ag | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors |
CN102127057A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US20090162286A1 (en) | 2004-06-07 | 2009-06-25 | Pfizer Inc. | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
UY29386A1 (es) * | 2005-02-21 | 2006-10-02 | Sanofi Aventis | Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2. |
NZ560268A (en) | 2005-03-02 | 2010-12-24 | Nycomed Gmbh | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
US8017633B2 (en) * | 2005-03-08 | 2011-09-13 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
-
2007
- 2007-09-04 US US12/310,547 patent/US20100179131A1/en not_active Abandoned
- 2007-09-04 NZ NZ574710A patent/NZ574710A/en not_active IP Right Cessation
- 2007-09-04 EP EP07803217A patent/EP2063890A1/en not_active Withdrawn
- 2007-09-04 WO PCT/EP2007/059253 patent/WO2008028914A1/en active Application Filing
- 2007-09-04 CA CA002662084A patent/CA2662084A1/en not_active Abandoned
- 2007-09-04 EP EP10005207A patent/EP2213289A1/en not_active Withdrawn
- 2007-09-04 AU AU2007293885A patent/AU2007293885A1/en not_active Abandoned
- 2007-09-04 ME MEP-85/09A patent/MEP8509A/xx unknown
- 2007-09-04 JP JP2009527131A patent/JP2010502670A/ja active Pending
- 2007-09-04 UA UAA200902891A patent/UA100497C2/ru unknown
- 2007-09-04 BR BRPI0716134-4A2A patent/BRPI0716134A2/pt not_active IP Right Cessation
- 2007-09-04 KR KR1020097006219A patent/KR20090047546A/ko not_active Application Discontinuation
- 2007-09-04 EA EA200900392A patent/EA200900392A1/ru unknown
- 2007-09-04 CN CN2007800332683A patent/CN101511364B/zh not_active Expired - Fee Related
- 2007-09-04 MX MX2009002282A patent/MX2009002282A/es not_active Application Discontinuation
-
2009
- 2009-01-22 ZA ZA2009/00501A patent/ZA200900501B/en unknown
- 2009-02-03 IL IL196869A patent/IL196869A0/en unknown
- 2009-03-26 NO NO20091260A patent/NO20091260L/no not_active Application Discontinuation
-
2012
- 2012-02-01 US US13/363,485 patent/US20120129817A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA200900501B (en) | 2010-02-24 |
US20120129817A1 (en) | 2012-05-24 |
IL196869A0 (en) | 2009-11-18 |
EP2213289A1 (en) | 2010-08-04 |
MEP8509A (en) | 2011-12-20 |
NZ574710A (en) | 2012-02-24 |
NO20091260L (no) | 2009-03-26 |
CA2662084A1 (en) | 2008-03-13 |
WO2008028914A1 (en) | 2008-03-13 |
EA200900392A1 (ru) | 2010-06-30 |
KR20090047546A (ko) | 2009-05-12 |
US20100179131A1 (en) | 2010-07-15 |
JP2010502670A (ja) | 2010-01-28 |
CN101511364A (zh) | 2009-08-19 |
MX2009002282A (es) | 2009-03-20 |
BRPI0716134A2 (pt) | 2013-09-17 |
EP2063890A1 (en) | 2009-06-03 |
AU2007293885A1 (en) | 2008-03-13 |
CN101511364B (zh) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA100497C2 (ru) | Комбинированное лечение сахарного диабета | |
MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
MX2007006178A (es) | Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular. | |
ZA200807274B (en) | Novel pyridine derivatives | |
MY154909A (en) | Novel thiophene derivatives | |
TW200700406A (en) | Novel thiophene derivatives | |
PL381247A1 (pl) | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze | |
TW200716591A (en) | Novel thiophene derivatives | |
CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
HK1132175A1 (en) | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity | |
TW200626068A (en) | Active compounds for seed treatment | |
TW200738670A (en) | Novel thiophene derivatives | |
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
MX2009002903A (es) | Combinacion de un ligando del receptor nmda y un compuesto con afinidad por el receptor 5-ht6. | |
UA95464C2 (en) | Pyridopyrazine derivatives and use thereof | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
TW200942524A (en) | Novel aminomethyl benzene derivatives | |
TW200800967A (en) | Benzimidazole thiophene compounds | |
IL190730A0 (en) | Potassium channel inhibitors | |
CL2008000629A1 (es) | Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer. | |
TW200626162A (en) | Agent for controlling demodicosis | |
WO2008073332A3 (en) | Creatine compositions for skin treatment |